House Dust Mite Allergy-Pipeline Review, H2 2015

House Dust Mite Allergy-Pipeline Review, H2 2015


  • Products Id :- GMDHC7023IDB
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

House Dust Mite Allergy-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'House Dust Mite Allergy-Pipeline Review, H2 2015', provides an overview of the House Dust Mite Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for House Dust Mite Allergy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the House Dust Mite Allergy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

House Dust Mite Allergy Overview 6

Therapeutics Development 7

Pipeline Products for House Dust Mite Allergy-Overview 7

Pipeline Products for House Dust Mite Allergy-Comparative Analysis 8

House Dust Mite Allergy-Therapeutics under Development by Companies 9

House Dust Mite Allergy-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

House Dust Mite Allergy-Products under Development by Companies 13

House Dust Mite Allergy-Companies Involved in Therapeutics Development 14

ALK-Abello A/S 14

Anergis SA 15

Biomay AG 16

Circassia Pharmaceuticals Plc 17

DBV Technologies S.A. 18

HAL Allergy BV 19

Stallergenes S.A. 20

House Dust Mite Allergy-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

AllerDM-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Allergen for House Dust Mite Allergy-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

BM-35-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

MK-8237-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

PL-103-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

STG-320-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Vaccine for Allergic Rhino-Conjunctivitis and House Dust Mite Allergy-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

House Dust Mite Allergy-Recent Pipeline Updates 39

House Dust Mite Allergy-Dormant Projects 44

House Dust Mite Allergy-Discontinued Products 45

House Dust Mite Allergy-Product Development Milestones 46

Featured News & Press Releases 46

Jun 09, 2015: ALK's partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal 46

Jun 04, 2015: ALK announces top-line results from its partner MSD's North American Phase III trial of house dust mite SLIT-tablet 46

Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet 47

Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet 48

Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development 48

Mar 04, 2014: Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet 49

Sep 12, 2013: Circassia's house dust mite allergy treatment achieves long-term symptom reduction 50

Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma 51

Jun 19, 2013: Anergis Files Provisional US Patent On AllerDM Dust Mite Allergy Treatment 52

Jun 19, 2013: ALK-Abello's New Allergy Immunotherapy Tablet Meets Primary Endpoint In Pivotal Phase III Trial In Patients With House Dust Mite Allergy 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

Number of Products under Development for House Dust Mite Allergy, H2 2015 7

Number of Products under Development for House Dust Mite Allergy-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Late Stage Development, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 11

Comparative Analysis by Early Stage Development, H2 2015 12

Products under Development by Companies, H2 2015 13

House Dust Mite Allergy-Pipeline by ALK-Abello A/S, H2 2015 14

House Dust Mite Allergy-Pipeline by Anergis SA, H2 2015 15

House Dust Mite Allergy-Pipeline by Biomay AG, H2 2015 16

House Dust Mite Allergy-Pipeline by Circassia Pharmaceuticals Plc, H2 2015 17

House Dust Mite Allergy-Pipeline by DBV Technologies S.A., H2 2015 18

House Dust Mite Allergy-Pipeline by HAL Allergy BV, H2 2015 19

House Dust Mite Allergy-Pipeline by Stallergenes S.A., H2 2015 20

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Stage and Target, H2 2015 22

Number of Products by Stage and Route of Administration, H2 2015 24

Number of Products by Stage and Molecule Type, H2 2015 26

House Dust Mite Allergy Therapeutics-Recent Pipeline Updates, H2 2015 39

House Dust Mite Allergy-Dormant Projects, H2 2015 44

House Dust Mite Allergy-Discontinued Products, H2 2015 45

List of Figures

Number of Products under Development for House Dust Mite Allergy, H2 2015 7

Number of Products under Development for House Dust Mite Allergy-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Late Stage Development, H2 2015 10

Comparative Analysis by Early Stage Products, H2 2015 12

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Top 10 Routes of Administration, H2 2015 23

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 23

Number of Products by Top 10 Molecule Types, H2 2015 25

Number of Products by Stage and Top 10 Molecule Types, H2 2015 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ALK-Abello A/S

Anergis SA

Biomay AG

Circassia Pharmaceuticals Plc

DBV Technologies S.A.

HAL Allergy BV

Stallergenes S.A.

House Dust Mite Allergy Therapeutic Products under Development, Key Players in House Dust Mite Allergy Therapeutics, House Dust Mite Allergy Pipeline Overview, House Dust Mite Allergy Pipeline, House Dust Mite Allergy Pipeline Assessment

select a license

Single User License
USD 2000 INR 129560
Site License
USD 4000 INR 259120
Corporate User License
USD 6000 INR 388680

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com